Christopher Gibson - 04 Feb 2026 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Kyle Nelson, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
04 Feb 2026
Net transactions value
-$201,696
Form type
4
Filing time
06 Feb 2026, 17:53:41 UTC
Previous filing
22 Jan 2026
Next filing
19 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gibson Christopher Director C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY /s/ Kyle Nelson, attorney-in-fact 06 Feb 2026 0001856369

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Conversion of derivative security $0 +40,000 +4.4% $0.000000 953,839 04 Feb 2026 Direct F1, F2
transaction RXRX Class A Common Stock Sale $164,800 -40,000 -4.2% $4.12 913,839 04 Feb 2026 Direct F2
transaction RXRX Class A Common Stock Award $0 +30,346 +3.3% $0.000000 944,185 06 Feb 2026 Direct F3
transaction RXRX Class A Common Stock Tax liability $36,896 -10,364 -1.1% $3.56 933,821 06 Feb 2026 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Class B Common Stock Conversion of derivative security $0 -40,000 -0.87% $0.000000 4,583,334 04 Feb 2026 Class A Common Stock 40,000 $0.000000 Direct F1
holding RXRX Class B Common Stock 386,000 04 Feb 2026 Class A Common Stock 0 $0.000000 by LAHWRAN-3 LLC F1, F5
holding RXRX Class B Common Stock 388,000 04 Feb 2026 Class A Common Stock 0 $0.000000 by LAHWRAN-4 LLC F1, F6
holding RXRX Class B Common Stock 50,000 04 Feb 2026 Class A Common Stock 0 $0.000000 by Gibson Family Trust F1, F7
holding RXRX Stock Option (Right to Buy) 1,050,567 04 Feb 2026 Class A Common Stock 0 $7.25 Direct F8
holding RXRX Stock Option (Right to Buy) 666,898 04 Feb 2026 Class A Common Stock 0 $10.09 Direct F9
holding RXRX Stock Option (Right to Buy) 813,600 04 Feb 2026 Class A Common Stock 0 $8.55 Direct F10
holding RXRX Stock Option (Right to Buy) 399,002 04 Feb 2026 Class A Common Stock 0 $11.40 Direct F11
holding RXRX Stock Option (Right to Buy) 5,436 04 Feb 2026 Class A Common Stock 0 $11.40 Direct
holding RXRX Stock Option (Right to Buy) 282,500 04 Feb 2026 Class A Common Stock 0 $2.48 Direct F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F2 This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
F3 This RSU vested immediately upon the grant date.
F4 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F5 The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
F6 The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
F7 The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
F8 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F9 The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F10 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F11 The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F12 The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.